0000000001305357

AUTHOR

C. Vila

showing 7 related works from this author

Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy

2007

In this randomized, double-blind, crossover clinical trial, adult patients treated two migraine attacks: one with almotriptan 12.5 mg and the other with ergotamine 2 mg plus caffeine 200 mg. Treatment with almotriptan was associated with a significantly greater proportion of patients achieving 2-h pain free (20.9% vs. 13.7%; P < 0.05) and 2-h pain relief (57.7% vs. 44.5%; P < 0.01) compared with ergotamine plus caffeine therapy; significant differences were not seen at 1 h. Rates for sustained pain free and sustained pain free plus no adverse events (AEs) also were significantly greater after almotriptan treatment than after the use of ergotamine plus caffeine (P < 0.05). Almotriptan was as…

business.industryNauseamedicine.diseaseCrossover studychemistry.chemical_compoundNeurologyMigrainechemistryAlmotriptanAnesthesiamedicineVomitingErgotamineNeurology (clinical)medicine.symptomAdverse effectCaffeinebusinessmedicine.drugEuropean Journal of Neurology
researchProduct

Home‐delivered ultrasound monitoring for home treatment of haemarthrosis in haemophilia A

2015

medicine.medical_specialtyFactor VIIIbusiness.industryUltrasoundHaemophilia AMEDLINEHome Care Services Hospital-BasedHematologyGeneral MedicineHospital basedHemophilia Amedicine.diseaseHemarthrosisEmergency medicineHumansMedicineHome treatmentUltrasonographybusinessGenetics (clinical)UltrasonographyHaemophilia
researchProduct

CCDC 607970: Experimental Crystal Structure Determination

2007

Related Article: G.Blay, I.Fernandez, B.Monje, M.C.Munoz, J.R.Pedro, C.Vila|2006|Tetrahedron|62|9174|doi:10.1016/j.tet.2006.07.036

Space GroupCrystallography(2S5S1'S)-2-t-Butyl-5-(1'3'-diphenyl-3'-oxopropyl)-5-phenyl-13-dioxolan-4-oneCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 767788: Experimental Crystal Structure Determination

2011

Related Article: G.Blay, I.Fernandez, M.C.Munoz, J.R.Pedro, C.Vila|2010|Chem.-Eur.J.|16|9117|doi:10.1002/chem.201000568

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters1-(4-Chlorophenyl)-444-trifluoro-3-(1H-indol-3-yl)butan-1-oneExperimental 3D Coordinates
researchProduct

CCDC 732229: Experimental Crystal Structure Determination

2010

Related Article: G.Blay, I.Fernandez, A.Monleon, M.C.Munoz, J.R.Pedro, C.Vila|2009|Adv.Synth.Catal.|351|2433|doi:10.1002/adsc.200900357

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters(S)-2-(5-Bromo-1H-indol-3-yl)-14-bis(4-methylphenyl)butane-14-dioneExperimental 3D Coordinates
researchProduct

CCDC 911096: Experimental Crystal Structure Determination

2013

Related Article: G.Blay,I.Fernandez,M.C.Munoz,J.R.Pedro,C.Vila|2013|Eur.J.Org.Chem.|2013|1902|doi:10.1002/ejoc.201201636

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters(R)-4-Benzyloxy-3-(5-bromo-1H-indol-3-yl)-1-(4-methylphenyl)butan-1-oneExperimental 3D Coordinates
researchProduct

CCDC 812138: Experimental Crystal Structure Determination

2012

Related Article: G.Blay, I.Fernandez, M.C.Munoz, J.R.Pedro, A.Recuenco, C.Vila|2011|J.Org.Chem.|76|6286|doi:10.1021/jo2010704

Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersEthyl 2-(4-chlorophenyl)-3-formamido-2-hydroxy-3-oxopropanoateExperimental 3D Coordinates
researchProduct